CNS Drugs

, Volume 23, Issue 10, pp 899–902 | Cite as

Spotlight on Buprenorphine/Naloxone in the Treatment of Opioid Dependence†

Adis Spotlight

Abstract

Buprenorphine/naloxone (Suboxone®) comprises the partial μ-opioid receptor agonist buprenorphine in combination with the opioid antagonist naloxone in a 4: 1 ratio. When buprenorphine/naloxone is taken sublingually as prescribed, the naloxone exerts no clinically significant effect, leaving the opioid agonist effects of buprenorphine to predominate. However, when buprenorphine/naloxone is parenterally administered in patients physically dependent on full agonist opioids, the opioid antagonism of naloxone causes withdrawal effects, thus reducing the abuse potential of the drug combination.

Buprenorphine/naloxone is an effective maintenance therapy for opioid dependence and has generally similar efficacy to methadone, although more data are needed. Less frequent dispensing of buprenorphine/naloxone (e.g. thrice weekly) does not appear to compromise efficacy and can improve patient satisfaction. Buprenorphine/naloxone is more effective than clonidine as a medically supervised withdrawal therapy. Moreover, buprenorphine/naloxone is a generally well tolerated medically supervised withdrawal and maintenance treatment. Thus, sublingual buprenorphine/naloxone is a valuable pharmacotherapy for the treatment of opioid dependence.

References

  1. 1.
    Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs 2009; 69(5): 577–607PubMedCrossRefGoogle Scholar
  2. 2.
    European Medicines Agency. Scientific discussion (Suboxone) [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/suboxone/069706en6.pdf [Accessed 2007 Jan 4]
  3. 3.
    Mégarbane B, Hreiche R, Pirnay S, et al. Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol Rev 2006; 25(2): 79–85PubMedCrossRefGoogle Scholar
  4. 4.
    Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978 Apr; 35(4): 501–16PubMedCrossRefGoogle Scholar
  5. 5.
    Bickel WK, Stitzer ML, Bigelow GE, et al. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 1988 Oct; 247(1): 47–53PubMedGoogle Scholar
  6. 6.
    Walsh SL, June HL, Schuh KJ, et al. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl) 1995; 119(3): 268–76CrossRefGoogle Scholar
  7. 7.
    Wesson DR. Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S. J Psychoactive Drugs 2004 May; Suppl. 2: 119–28PubMedCrossRefGoogle Scholar
  8. 8.
    US Department of Health and Human Services. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: a treament improvement protocol TIP 40 [online]. Available from URL: http://www.naabt.org/links/TIP_40_PDF.pdf [Accessed 2007 Mar 1]
  9. 9.
    Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994 May; 55(5): 569–80PubMedCrossRefGoogle Scholar
  10. 10.
    Ciraulo DA, Hitzemann RJ, Somoza E, et al. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. J Clin Pharmacol 2006; 46: 179–92PubMedCrossRefGoogle Scholar
  11. 11.
    Eissenberg T, Greenwald MK, Johnson RE, et al. Buprenorphine’s physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther 1996; 276(2): 449–59PubMedGoogle Scholar
  12. 12.
    Endo Laboratories. Narcan® (naloxone hydrochloride injection) label [online]. Available from URL: http://www.fda.gov [Accessed 2007 Jan 30]
  13. 13.
    European Medicines Agency. Suboxone: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/suboxone/H-697-PI-en.pdf [Accessed 2009 Feb 11]
  14. 14.
    Reckitt Benckiser Pharmaceuticals, Inc. Suboxone (buprenorphine HCl and naloxone HCl dihydrate sublingual tablets)/ Subutex (buprenorphine HCl sublingual tablets): US prescribing information [online]. Available from URL: http://www.suboxone.com/patients/pi/ [Accessed 2009 Feb 11]
  15. 15.
    Mendelson J, Jones RT, Welm S, et al. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berl) 1999 Jan; 141(1): 37–46CrossRefGoogle Scholar
  16. 16.
    Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003 Sep 4; 349(10): 949–58PubMedCrossRefGoogle Scholar
  17. 17.
    Kamien JB, Branstetter SA, Amass LA. Buprenorphine-naloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid dependent patients. Heroin Addict Relat Clin Probl 2008; 10(4): 5–18Google Scholar
  18. 18.
    Kakko J, Grönbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007 May; 164(5): 797–803PubMedCrossRefGoogle Scholar
  19. 19.
    Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006 Jul 27; 355(4): 365–74PubMedCrossRefGoogle Scholar
  20. 20.
    Bell J, Shanahan M, Mutch C, et al. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 2007 Dec; 102(12): 1899–907PubMedCrossRefGoogle Scholar
  21. 21.
    Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend 2000 Feb 1; 58(1–2): 143–52PubMedCrossRefGoogle Scholar
  22. 22.
    Amass L, Kamien JB, Mikulich SK. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 2001 Jan 1; 61(2): 173–81PubMedCrossRefGoogle Scholar
  23. 23.
    Ling W, Amass L, Shoptaw S, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005 Aug; 100(8): 1090–100PubMedCrossRefGoogle Scholar
  24. 24.
    Ling W, Hillhouse M, Domier C, et al. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009 Feb; 104(2): 256–65PubMedCrossRefGoogle Scholar
  25. 25.
    Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 2008 Nov 5; 300(17): 2003–11PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Adis, a Wolters Kluwer BusinessMairangi Bay, North Shore 0754, AucklandNew Zealand

Personalised recommendations